Armata Pharmaceuticals, Inc. (ARMP)

[lesgetrich]

Synthetic Genomics, Inc now owns 5.2% of Armata.

ARMP SC 13G

Synthetic Genomics, Inc website

Synthetic Genomics, Inc. (SGI) is a leader in the genomics revolution. SGI was founded in 2005 by genomics pioneers Craig Venter, Ph.D., and Nobel Laureate Hamilton Smith, M.D., shortly after the completion of the Human Genome Project, which mapped the human genome for the first time. Since then, scientists and engineers have dramatically improved the accuracy and reduced the cost associated with reading the sequence of DNA code — the order of the As, Cs, Ts, and Gs that make up an organism’s genome...

...Phage therapy has the potential to treat multidrug-resistant bacterial infections. Engineered phage can solve inherent limitations of natural phage, such as narrow host-range and resistance development. Synthetic Genomics has developed a proprietary bacteriophage engineering platform to address the inherent limitations of natural phage as a therapeutic. Armata Pharmaceuticals is deploying the Synthetic Genomics IP to generate clinical candidates and bacteriophage therapies.